Recent review article

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 1670
Joined: Fri Jul 20, 2018 5:13 pm

Recent review article

Post by biopearl123 » Wed Oct 24, 2018 5:58 pm

Hat tip to Richard on YMB for providing this reference: http://www.bloodadvances.org/content/2/ ... ecked=true

I will try to post the table which shows Imetelstat furtherest along in development compared with other new potential treatments. The article highlights the fact that no new drugs have been approved in the past ten years for MDS. Looking a mechanisms, its hard to get more "upstream" than treating the malignant clone and CSC itself. Several new agents in development are discussed including Imetelstat. bp

biopearl123
Posts: 1670
Joined: Fri Jul 20, 2018 5:13 pm

Re: Recent review article

Post by biopearl123 » Wed Oct 24, 2018 6:06 pm

Attempted to copy Table 1. Not successful in a readable way. Note that Imetelstat entering Phase III but some therapies already listed as P III with most in earlier stages of development. Nonetheless in terms of targeting that malignant clone directly and upstream, it appears that Imetelstat has a unique MOA. Anyway the article is worth a read. Awaiting ASH with great interest. bp

nerdyboy99
Posts: 7
Joined: Wed Jul 25, 2018 6:33 pm

Re: Recent review article

Post by nerdyboy99 » Wed Oct 24, 2018 9:56 pm

Image

Post Reply